Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.64 - $31.88
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.64M
Market Cap
$13.67B
Enterprise Value$13.14B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)12.4
Beta0.69
Next Earnings
May 08, 2025EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding661,871,800
10 Day Avg. Volume1,683,172
30 Day Avg. Volume1,643,288
Standard Deviation0.10
R-Squared0.26
Alpha-0.00951
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.29
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.40Price Target Upside70.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Genmab News
PremiumCompany Announcements
Genmab’s Strong Earnings Call Highlights Growth and Optimism
PremiumCompany Announcements
Genmab A/S Announces Annual General Meeting
PremiumCompany Announcements
Genmab’s 2024 Achievements and Future Prospects
PremiumCompany Announcements
Genmab A/S Celebrates 25 Years with Key Acquisitions and ESG Milestones---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGMAB reported 2024 revenues that were modestly above consensus estimates, highlighting growth in key areas such as Darzalex and Kesimpta royalties.
Pipeline DevelopmentThe announcement of a Phase III study for Rina-S in endometrial cancer indicates continued pipeline development and potential future opportunities.
Stock UpgradeThe analyst is upgrading GMAB stock to OP, indicating a positive long-term outlook despite potential near-term volatility.
Bears Say
Market PenetrationRisks also involve the inability of ARZERRA to achieve substantial market penetration in relapsing multiple sclerosis.
Patent IssuesThe price target is being lowered to $20, based on a reduced P/E multiple due to the increasing likelihood of Darzalex patent issues in 2030/31.
Sales RisksRisks include slowing DARZALEX sales and failure to obtain DARZALEX label extensions.
---
Ownership Overview
―
Insiders
1.15% Mutual Funds
2.37% Other Institutional Investors
95.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $18.64 and its highest was $31.88 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $13.67B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 08, 2025 which is in 76 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 12, 2025. The company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.374 by $0.466.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.23.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,871,800 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.84 in its last earnings report, beating expectations of $0.374. Following the earnings report the stock price went up 4.235%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
---
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.40 (70.23% Upside)
$37.40 (70.23% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 42.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.47%
12-Months-Change
Fundamentals
Return on Equity
23.16%
Trailing 12-Months
Asset Growth
21.65%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with significant revenue and profit growth, driven by the success of commercialized medicines like EPKINLY and TIVDAK. The company has a robust pipeline with strategic investments and provided optimistic guidance for 2025. However, there are minor concerns about EPKINLY's flat sales in Q4 and the company's dependency on key products amid competitive pressures.Read More>---
GMAB Stock 12 Month Forecast
Average Price Target
$37.40
▲(70.23% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-19.80%
reiterated a buy rating 9 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -19.80% per trade.
---